Stock Scorecard
Stock Summary for Protagenic Therapeutics Inc (PTIX) - $3.20 as of 10/16/2025 7:23:06 AM EST
Total Score
8 out of 30
Safety Score
17 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PTIX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PTIX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PTIX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PTIX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PTIX (17 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 3 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for PTIX
Financial Details for PTIX
Company Overview |
|
|---|---|
| Ticker | PTIX |
| Company Name | Protagenic Therapeutics Inc |
| Country | USA |
| Description | Protagenic Therapeutics, Inc. (PTIX) is a preclinical biopharmaceutical firm headquartered in New York, specializing in the development of innovative therapies aimed at treating stress-related mood and neuropsychiatric disorders. The company utilizes advanced research methodologies and cutting-edge technologies to identify and address significant unmet medical needs within this vital sector. With a strong commitment to enhancing patient mental health outcomes, Protagenic Therapeutics is positioning itself as a promising investment opportunity for institutional investors focused on advancing transformative healthcare solutions in an essential and expanding market. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 3.20 |
| Price 4 Years Ago | 77.56 |
| Last Day Price Updated | 10/16/2025 7:23:06 AM EST |
| Last Day Volume | 58,616 |
| Average Daily Volume | 104,633 |
| 52-Week High | 15.26 |
| 52-Week Low | 2.25 |
| Last Price to 52 Week Low | 42.22% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.62 |
| Sector PE | 41.01 |
| 5-Year Average PE | -44.25 |
| Free Cash Flow Ratio | 1.50 |
| Industry Free Cash Flow Ratio | 14.94 |
| Sector Free Cash Flow Ratio | 29.61 |
| Current Ratio Most Recent Quarter | 0.41 |
| Total Cash Per Share | 2.14 |
| Book Value Per Share Most Recent Quarter | -2.15 |
| Price to Book Ratio | 1.61 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.01 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.05 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.01 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 1,914,900 |
| Market Capitalization | 6,127,680 |
| Institutional Ownership | 10.10% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 5.30% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -10.50% |
| Reported EPS 12 Trailing Months | -13.13 |
| Reported EPS Past Year | -4.12 |
| Reported EPS Prior Year | -1.89 |
| Net Income Twelve Trailing Months | -8,692,523 |
| Net Income Past Year | -5,525,000 |
| Net Income Prior Year | -5,000,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 4,096,189 |
| Total Cash Past Year | 1,838,469 |
| Total Cash Prior Year | 1,287,893 |
| Net Cash Position Most Recent Quarter | 4,096,189 |
| Net Cash Position Past Year | 1,838,469 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 150,591 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | 1,013,154 |
| Total Stockholder Equity Prior Year | 3,668,117 |
| Total Stockholder Equity Most Recent Quarter | -3,974,012 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -3,240,738 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.69 |
| Free Cash Flow Past Year | -4,216,517 |
| Free Cash Flow Prior Year | -3,853,551 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.10 |
| MACD Signal | -0.01 |
| 20-Day Bollinger Lower Band | 2.63 |
| 20-Day Bollinger Middle Band | 3.45 |
| 20-Day Bollinger Upper Band | 4.26 |
| Beta | 0.38 |
| RSI | 38.76 |
| 50-Day SMA | 14.32 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 22.38 |
System |
|
| Modified | 10/16/2025 7:23:07 AM EST |